Literature DB >> 19644229

The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive symptoms in schizophrenia.

Sung-Wan Kim1, Il-Seon Shin, Jae-Min Kim, Tak Youn, Su-Jin Yang, Michael Y Hwang, Jin-Sang Yoon.   

Abstract

Atypical antipsychotics have been reported to induce or exacerbate obsessive-compulsive symptoms (OCS) in patients with schizophrenia. We report the development of de novo obsession induced by sequential treatment with risperidone, aripiprazole, and ziprasidone, which have an antagonist effect on serotonin 5-HT(2A) receptors in a patient with schizophrenia. The obsession was repeatedly improved after switching the atypical antipsychotics to amisulpride, a selective D(2) and D(3) receptor antagonist. To our knowledge, this is the first report about ziprasidone-induced OCS in a patient with schizophrenia. In conclusion, this case supports the hypothesis that the antagonist effect on 5-HT(2) receptors may be related to atypical antipsychotic-induced OCS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19644229     DOI: 10.1097/WNF.0b013e318184fafd

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  4 in total

Review 1.  Second generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia: a review of the experimental literature.

Authors:  Trehani M Fonseka; Margaret A Richter; Daniel J Müller
Journal:  Curr Psychiatry Rep       Date:  2014-11       Impact factor: 5.285

2.  Haloperidol induced obsessive compulsive symptom (OCS) in a patient with learning disability and bipolar affective disorder.

Authors:  Inam Ulhaq; Adam Abba-Aji
Journal:  BMJ Case Rep       Date:  2012-03-08

3.  Comorbidity in Schizophrenia: Conceptual Issues and Clinical Management.

Authors:  Hussain Muhammad Abdullah; Hameed Azeb Shahul; Michael Y Hwang; Stephen Ferrando
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-11-05

Review 4.  Augmentation with antidepressants in schizophrenia treatment: benefit or risk.

Authors:  Ye-Meng Mao; Ming-Dao Zhang
Journal:  Neuropsychiatr Dis Treat       Date:  2015-03-16       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.